86. Pulmonary arterial hypertension Clinical trials / Disease details

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01934647 (ClinicalTrials.gov)	November 22, 2013	30/8/2013	Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)	A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: MK-8892	Merck Sharp & Dohme Corp.	NULL	Terminated	18 Years	70 Years	All	7	Phase 1	Germany
2	NCT01926509 (ClinicalTrials.gov)	November 14, 2013	19/8/2013	Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)	A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: MK-8892;Drug: Placebo for MK-8892	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	70 Years	All	23	Phase 1	Bulgaria;Germany;Moldova, Republic of
3	NCT01798849 (ClinicalTrials.gov)	March 15, 2013	22/2/2013	A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)	A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892	Pulmonary Arterial Hypertension	Drug: MK-8892;Drug: Placebo for MK-8892	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	60 Years	Male	25	Phase 1	Belgium